Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Cassava Sciences, Inc. is a biotechnology company focused on developing investigational treatments for central nervous system disorders, particularly Tuberous Sclerosis Complex-related epilepsy [1][4] - The company will participate in the H.C. Wainwright 27 Annual Global Investment Conference scheduled for September 8-10, 2025, in New York City [1][2] Company Overview - Cassava Sciences is based in Austin, Texas, and is developing a proprietary oral small molecule called simufilam, which is believed to modulate the activity of the filamin A protein, impacting neuronal development [4] - The company aims to address various CNS disorders with its investigational treatments [4] Conference Details - Rick Barry, the President and CEO of Cassava, will present at the conference on September 8, 2025, at 5 PM ET [2] - A replay of the webcast will be available on the Cassava Investor's website for approximately 90 days post-event [2]